Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Thomas

Showing results (161-170 of 300) with videos related to

Pageof 30
Sort By:
Neurochemical Research|May 17, 2017
Disease-Modifying Effects of Neural Regeneration Peptide 2945 in the GAERS Model of Absence EpilepsyGabi Dezsi, Frank Sieg, Mark Thomas, et al.
Internal Medicine Journal|January 12, 2024
Fabry-specific treatment in Australia: time to align eligibility criteria with international best practicesKathleen Nicholls, Charles Denaro, Michel Tchan, et al.
Learning Health Systems|October 20, 2023
Which computable biomedical knowledge objects will be regulated? Results of a UK workshop discussing the regulation of knowledge libraries and software as a medical deviceJeremy C Wyatt, Philip Scott, Johan Ordish, et al.
Journal of Cell Science|August 5, 2005
Improved muscle healing through enhanced regeneration and reduced fibrosis in myostatin-null miceSeumas McCroskery, Mark Thomas, Leanne Platt, et al.
Transplantation|November 19, 2009
Fatal human herpesvirus-6 infection after renal transplantationHelen Pilmore, John Collins, Ian Dittmer, et al.
The American Journal of Cardiology|March 10, 2009
Causes and consequences of nonpersistence with heart failure medicationMary Mockler, Christina O'Loughlin, Niamh Murphy, et al.
International Journal of Medical Informatics|May 22, 2018
The impact of using an intravenous workflow management system (IVWMS) on cost and patient safetyAlex C Lin, Yihong Deng, Hilal Thaibah, et al.
JIMD Reports|February 23, 2013
Effect of reduced agalsidase Beta dosage in fabry patients: the Australian experienceJoanna Ghali, Kathy Nicholls, Charles Denaro, et al.
The Gerontologist|June 15, 2007
Characteristics of residents and providers in the assisted living pilot programSusan Hedrick, Marylou Guihan, Michael Chapko, et al.
Orphanet Journal of Rare Diseases|January 15, 2020
Prevalence of Fabry disease in dialysis patients: Western Australia Fabry disease screening study - the FoRWARD studySadia Jahan, Subashini Sarathchandran, Shamina Akhter, et al.
Pageof 30

Showing results (161-170 of 300) with videos related to

Sort By:
Pageof 30
Neurochemical Research|May 17, 2017
Disease-Modifying Effects of Neural Regeneration Peptide 2945 in the GAERS Model of Absence EpilepsyGabi Dezsi, Frank Sieg, Mark Thomas, et al.
Internal Medicine Journal|January 12, 2024
Fabry-specific treatment in Australia: time to align eligibility criteria with international best practicesKathleen Nicholls, Charles Denaro, Michel Tchan, et al.
Learning Health Systems|October 20, 2023
Which computable biomedical knowledge objects will be regulated? Results of a UK workshop discussing the regulation of knowledge libraries and software as a medical deviceJeremy C Wyatt, Philip Scott, Johan Ordish, et al.
Journal of Cell Science|August 5, 2005
Improved muscle healing through enhanced regeneration and reduced fibrosis in myostatin-null miceSeumas McCroskery, Mark Thomas, Leanne Platt, et al.
Transplantation|November 19, 2009
Fatal human herpesvirus-6 infection after renal transplantationHelen Pilmore, John Collins, Ian Dittmer, et al.
The American Journal of Cardiology|March 10, 2009
Causes and consequences of nonpersistence with heart failure medicationMary Mockler, Christina O'Loughlin, Niamh Murphy, et al.
International Journal of Medical Informatics|May 22, 2018
The impact of using an intravenous workflow management system (IVWMS) on cost and patient safetyAlex C Lin, Yihong Deng, Hilal Thaibah, et al.
JIMD Reports|February 23, 2013
Effect of reduced agalsidase Beta dosage in fabry patients: the Australian experienceJoanna Ghali, Kathy Nicholls, Charles Denaro, et al.
The Gerontologist|June 15, 2007
Characteristics of residents and providers in the assisted living pilot programSusan Hedrick, Marylou Guihan, Michael Chapko, et al.
Orphanet Journal of Rare Diseases|January 15, 2020
Prevalence of Fabry disease in dialysis patients: Western Australia Fabry disease screening study - the FoRWARD studySadia Jahan, Subashini Sarathchandran, Shamina Akhter, et al.
Pageof 30